Titan Biotech Limited has announced that its Board of Directors will convene on February 12, 2026, to review and approve the company's third quarter financial results for FY26. The meeting represents a key milestone in the company's quarterly reporting cycle and regulatory compliance obligations.

Board Meeting Details

The board meeting has been scheduled with specific parameters and agenda items that reflect standard corporate governance practices:

Financial Results Scope

The board will consider and approve comprehensive financial statements covering multiple reporting formats:

• Unaudited standalone financial results for the third quarter ended December 31, 2025
• Unaudited consolidated financial results for the same period
• Any other business matters with the Chair's permission

Trading Window Restrictions

Titan Biotech Limited has implemented trading restrictions in accordance with regulatory requirements. The trading window for designated persons closed on January 1, 2026, following prior intimation dated December 22, 2025. This closure aligns with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal Code of Conduct for Prevention of Insider Trading.

Regulatory Compliance

The company has fulfilled its disclosure obligations under Regulation 29 read with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary and Compliance Officer Charanjit Singh has signed the formal intimation to BSE Limited, ensuring transparency and adherence to listing requirements.

The notification was submitted to BSE Limited on February 3, 2026, providing adequate advance notice to stakeholders and market participants about the upcoming board meeting and financial results announcement.

Titan Biotech Limited has announced significant changes to its board committee composition, effective January 2, 2026. The pharmaceutical company's Board of Directors approved the reconstitution of four key committees during a meeting held on January 2, 2026, appointing two new Independent Directors to strengthen its governance framework.

Key Appointments

The company has appointed Mr. Brijesh Kumar Singh and Mr. Debendra Kumar Sabat as members across all four reconstituted committees. Both individuals join as Independent Directors, bringing additional expertise to the company's governance structure.

Committee Reconstitution Details

Audit Committee

The reconstituted Audit Committee now comprises five members:

Nomination & Remuneration Committee

The committee maintains its five-member structure with the new appointments:

Additional Committee Changes

Corporate Social Responsibility Committee

The CSR Committee now includes five members following the reconstitution, with Mr. Rohit Jain continuing as Chairperson and the two new Independent Directors joining as members alongside existing members Mr. Naresh Kumar Singla and Mr. Abhishek Agarwal.

Stakeholders Relationship Committee

The Stakeholders Relationship Committee has been expanded to six members, maintaining Mr. Rohit Jain as Chairperson while adding the two new Independent Directors to the existing team of Mr. Naresh Kumar Singla, Mr. Suresh Chand Singla, and Mr. Dhairya Madan.

Meeting Details

The board meeting that approved these changes commenced at 2:30 PM and concluded at 3:10 PM on January 2, 2026. The company has communicated these changes to BSE Limited under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring compliance with regulatory requirements for corporate governance disclosures.